哪里想瘦打哪里！FDA批准Kythera药剂药物上市在即

你才双下巴，你全家都双下巴！只不过爱美自是人皆有之。如果说赘肉是每一个努力仅有美妙身材的“妹纸”或“汉纸”的大敌，那么一个喜感十足的双下巴算得是这些人的生死仇敌了。每一分钟，为数众多都有人为自己的一张大饼脸而感到自觉，虽然仅有一个肉感十足的双下巴捏进去是挺有肉感的，但是还是有很多人的同龄使其无法支撑一个双下巴之重。您可千万别笑，这甚至已经催生出一个庞大的美国市场。根据美国指甲整形协会的调查结果研究显示，68%的美国人对自己的双下巴透露了“厌倦”之情。而有鉴于此，在在Kythera新公司向FDA提交了其专门消灭双下巴的化妆施用德式类固醇ATX-101。这种类固醇完成了许多“胖纸”梦寐以求的功能，哪里想瘦打哪里，算得是定时失眠。不要以为这种近乎懦弱的类固醇只是一个笑话，在FDA所属的指甲和门诊类固醇专员会的无记名投票里面，领域专家可是以17：0的超高高票相反赞同其母公司。或许是因为这些领域专家里面也有很多饱受双下巴之苦吧。FDA也将方案于今年的5月13日之后对其作出再次决定。如果一切顺利的话，Kythera新公司方案于今年下半年将该产品母公司，分析社会大众预料这一类固醇的年销售额将将近3亿美元之多。随着化妆类固醇美国市场的大为加大，Kythera新公司算得是下了一步好棋。新公司于去年以8400万美元的定价从其前密切合作伙伴后发手里面出让了这种类固醇的全部自由权。而Kythera新公司也努力以此为契机在化妆类固醇美国市场里面渡河拔寨。就在上个月，Kythera新公司和Actelion新公司已达成商业价值2700万美元的密切合作协议，共同开发一种受挫过的抗炎症类固醇，而这种类固醇被确信或许开发出一种治疗法脱发的类固醇。概要英文报导：Kythera ($KYTH) won the unanimous support of an FDA advisory panel for its fat-busting injection, rolling toward approval with a first-of-its-kind treatment.The agency's independent Dermatologic and Ophthalmic Drugs Advisory Committee voted 17-0 that the drug's benefits outweighed its risks for patients looking to reduce submental fat, or double chin. The FDA is not required to follow its panels' votes, though it most commonly does, and the agency has promised to make a final decision on the injection by May 13. If all goes according to plan, Kythera plans to launch the drug, ATX-101, in the second half of this year.The biotech's shares he more than tripled since it pulled off a $73 million IPO in 2012, rising steadily as investors bet ATX-101 can carve out a space on the aesthetic market and potentially lure a Big Pharma acquirer. Kythera is pitching the injection as a much-needed nonsurgical option for double chin reduction, citing an American Society for Dermatologic Surgery survey that estimates 68% of Americans are "bothered" by submental fat.Kythera regained full rights to ATX-101's potential last year, orchestrating an $84 million deal to buy out ex-partner Bayer. And the drug, a synthetic version of the fat-blasting deoxycholic acid, could bring in more than $300 million a year once approved, Leerink yst Seamus Fernandez has said."This milestone demonstrates our commitment to developing first-in-class aesthetic products through a focus on scientific rigor and innovation," Kythera CEO Keith Leonard said in a statement. "At Kythera, we remain focused on investing in novel treatments that will allow aesthetic physicians to better meet the needs of their patients."Kythera is also focused on raising some cash now that it has a likely approval ahead. The biotech filed for a $125 million offering as soon as the market closed on Monday. Its share price was down several points at the end of the day.Beyond its top prospect, Kythera is working to build out a pipeline of aesthetic medicines. Last month, the California biotech signed a $27 million deal with Actelion ($ATLN) to get its hands on a once-failed anti-inflammatory medicine that could he a future as a treatment for hair loss.